AI
ORKA

Allostery Investments’s Oruka Therapeutics ORKA Stock Holding History

Allostery Investments’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$205K – 45
2025
Q1 		$205K Hold
20,000
– – 0.3% 32
2024
Q4 		$388K Buy
+20,000
New +$488K 0.41% 35

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Allostery Investments's ORKA Position: Q2 2025 in Review

Allostery Investments sold out of Oruka Therapeutics (ORKA) in Q2 2025, closing a stake of 20,000 shares — an estimated $205K sold.

Allostery Investments first reported a position in ORKA in Q4 2024 and held it in 2 quarters. The position peaked at $388K in Q4 2024. 81 funds tracked by Wall St. Rank hold ORKA as of Q2 2025.

  • Allostery Investments reported no remaining Oruka Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Allostery Investments sold 20,000 Oruka Therapeutics shares in Q2 2025, an estimated $205K.
  • Allostery Investments first reported a position in Oruka Therapeutics in Q4 2024 and held it in 2 quarters.
  • Allostery Investments's Oruka Therapeutics position peaked at $388K in Q4 2024.
  • 81 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2025.

Based on Allostery Investments's 13F filing for Q2 2025, filed 14 Aug 2025.